Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis

Inclusion Criteria: 1. meet hemophagocytic lymphohistiocytosis (HLH)-04 diagnostic criteria; 2. treated with HLH-94 no less than 2 weeks before enrollment and did not achieve at least PR; or relapsed patients after remission； 3. Life expectancy exceeds 1 month; 4. Age≥1 year old and ≤75 years old, gender is not limited； 5. Before the start of the study, total bilirubin ≤ 10 times the upper limit of normal; serum creatinine ≤ 1.5 times normal； 6. Serum human immunodeficiency virus(HIV) antigen or antibody negative； 7. Hepatitis C virus (HCV) antibody is negative, or HCV antibody is positive, but HCV RNA is negative； 8. Both hepatitis B virus (HBV) surface antigen and HBV core antibody were negative. If any of the above is positive, peripheral blood hepatitis B virus DNA titer should be detected, and less than 1×103 copies/ml can enter the group； 9. Informed consent. Exclusion Criteria: 1. Pregnancy or lactating Women； 2. Allergic to ruxolitinib； 3. Active bleeding of the internal organs； 4. uncontrollable infection； 5. Serious mental illness; 6. Non-melanoma skin cancer history; 7. Patients unable to comply during the trial and/or follow-up phase; 8. Participate in other clinical research at the same time.